August 19, 2026

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

Announcement of UDC Patent Approval (China)

HEALIOS K.K. ("Healios") is involved in the research of new therapeutic products using Universal Donor Cells ("UDCs")*, which are next-generation iPS cells created with gene-editing technology that have a reduced risk of immune rejection regardless of a patient's HLA type. We are pleased to announce that a patent (hereinafter referred to as the "Patent") for Helios UDC, for which Healios had filed an application, has been granted in the People's Republic of China (hereinafter referred to as "China").

1. Overview of the Approved Patent

- **Title of the Invention**: Low-immunogenic cells
- **Patent Number**: ZL202180037981.5
- **Patent Holder**: HEALIOS K.K.

2. Key Features of UDC Technology

Healios UDC is a hypoimmunogenic iPS cell developed through genetic editing to remove polymorphic HLA and introduce HLA-G, PD-L1, and PD-L2 genes, thereby granting resistance to both acquired and innate immunity. Furthermore, a "suicide gene" has been incorporated as a safety mechanism. This technology is expected to serve as a next-generation platform for regenerative medical products as a raw material for transplanted cells. In 2020, we successfully established a clinical-grade UDC line (clinical line), which has since been supplied to research institutions and companies worldwide as a promising raw material for cell-based medicines, enabling the investigation of their potential applications in treating various diseases.

The Healios UDC patent was granted in Japan in August 2025. (Announced on August 15, 2025, in the "Announcement of UDC Patent Approval (Japan)"). With the approval of the Patent, the uniqueness and novelty of our technology have been officially recognized in Japan. Additionally, this Patent has been filed not only in China but also in other countries, including Europe and the United States, where the patent examination processes are advancing successfully. This achievement enhances our competitive edge both domestically and globally. We aim to position our UDC as an industry-standard product, facilitating joint research and licensing agreements, and driving forward the field of regenerative medicine on a global scale.

3. Future Outlook

This matter has no impact on our consolidated financial results of the fiscal year ending December 31, 2026 at this time. We will promptly announce any matters that should be disclosed in the future.

* UDC

UDCs are iPS cells created using gene-editing technology that allows them to avoid and / or reduce the body's immune rejection response. The production of Healios' UDCs involve the removal of certain HLA genes that elicit a rejection response and the introduction of certain

genes to improve immune evasion and safety in an allogeneic iPS cell. This next-generation technology platform allows for the creation of regenerative medicine products with enhanced safety and a lower risk of immune rejection, while preserving the inherent ability of iPS cells to replicate themselves continuously and their pluripotency in differentiating into various other kinds of cells.

About Healios:

HEALIOS K.K. is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells. In the somatic stem cell field, Healios is developing HLCM051(invimestrocel), a proprietary cell product comprised of multipotent adult progenitor cells ("MAPCs") derived from the bone marrow of healthy adult donors. HLCM051 has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in hundreds of patients across multiple indications. Healios is seeking to advance HLCM051 on a global basis for ARDS, trauma, and ischemic stroke. In the iPSC regenerative medicine field, Healios has developed HLCN061, a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-modification. These cells have demonstrated robust anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process. The development of AKT-01/HLCN061 is currently being led by our development partner, Akatsuki Therapeutics, Inc., in preparation for the initiation of clinical trials. Healios has also established a proprietary, gene-edited "universal donor" induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).
https://www.healios.co.jp/en

Contact:
IR & PR Division
HEALIOS K.K.
E-mail: ir@healios.jp